Castle Biosciences CEO Derek J. Maetzold disposes of $516,747 in common shares
CSTL•CEO Derek J. Maetzold exercised options for 8,165 shares at $2.39 and sold 8,580 shares at a weighted-average $35.566 on Oct. 5, 2026; trusts tied to him sold another 5,916 shares.
1. Insider share transactions
Maetzold exercised stock options for 8,165 Castle Biosciences shares at $2.39 on Oct. 5, 2026, and sold 8,580 shares at a weighted-average price of $35.566. Separate trusts tied to him sold 5,916 shares at the same weighted-average price, and his directly held common stock ended at 21,064 shares.
